The antithrombotic potential of dalteparin in man assessed indirectly by Wessler's technique.
The aim of this study was to demonstrate the effectiveness of a new experimental approach for assessing the antithrombotic potential of low molecular weight heparins (LMWH) such as dalteparin. In this approach, sera obtained from healthy volunteers treated with various i.v. doses of dalteparin (30, 60 or 120 anti-Xa IU/kg) or placebo (physiological saline) were used as the thrombogenic challenge in a Wessler's stasis model of experimental venous thrombosis in the rat. Sera from placebo-treated volunteers showed a stable thrombogenic activity (0.25 ml/kg of serum producing thrombi of about 50 mg wet weight). Sera from healthy volunteers having previously received dalteparin however demonstrated dose- and time-related reductions in their thrombogenic activity. Half-lives of these effects were 300. 444 and > 480 min for 30, 60 and 120 anti-Xa IU/kg dalteparin respectively. These values were significantly higher than the corresponding anti-Xa and anti-IIa half-lives.
Millet
J
J
Laboratoires Fournier SCA, Daix, France.
Theveniaux
J
J
Tachon
G
G
Bogaievsky
Y
Y
Grippat
J C
JC
Samama
M
M
Brown
N L
NL
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage*; D001777:Blood Coagulation / Q000187:drug effects; D017985:Dalteparin / Q000008:administration & dosage*; D006801:Humans; D051381:Rats; D013924:Thrombophlebitis / Q000097:blood / Q000188:drug therapy*
D000925:Anticoagulants; D017985:Dalteparin